Patent 9402827 was granted and assigned to Ardea Biosciences, Inc. on August, 2016 by the United States Patent and Trademark Office.
Sodium 2-(5-bromo-4-(4-cyclopropyl-naphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate is described. In addition, pharmaceutical compositions and uses such compositions for the treatment of a variety of diseases and conditions.